# GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

> **NCT02319577** · PHASE2 · UNKNOWN · sponsor: **IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy** · enrollment: 80 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** oral vinorelbine
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT02319577
- **Lead sponsor:** IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319577, "GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02319577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*